证券代码：688029 证券简称：南微医学 公告编号：2025-049 一、减持主体减持前基本情况 南微医学科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，深圳市中科招商创业投资有限公司（以下简称"中科 招商"）持有南微医学科技股份有限公司（以下简称"公司"）股份 41,752,818 股，占公司总股本的 22.2270%。上述股份来源为公司首次公开发行股票并上市 前取得的股份，及该等股份于公司 2022 年实施资本公积转增股本时获得股份， 上述股份已于 2022 年 7 月 22 日起上市流通。 减持计划的实施结果情况 2025 年 8 月 18 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《南微医学科技股份有限公司持股 5%以上股东减持股份计划公告》（公告编号： 2025-036），公司股东中科招商拟通过上海证券交易所交易系统以集中竞价、大 宗交易方式减持公司股份合计不超过 ...

南财智讯12月5日电，南微医学公告，公司股东深圳市中科招商创业投资有限公司（简称"中科招商"） 在2025年9月30日至2025年10月9日期间，通过集中竞价交易方式合计减持公司股份62,000股，占公司总 股本的0.03%，减持价格区间为97.50至100.90元/股，累计减持金额622.49万元。本次减持后，中科招商 持股比例由22.2270%下降至22.1940%。截至2025年12月5日，本次减持计划期限届满，实际减持数量未 完成原计划的3,756,948股，剩余3,694,948股未实施减持。本次减持行为符合相关法律法规及此前披露的 减持计划。 ...

Core Insights - As of December 2, a total of 128 stocks in the Shanghai and Shenzhen markets have experienced net buying through financing for five consecutive days or more [1] - The stock with the longest consecutive net buying days is Zhongchen Technology, which has seen net buying for 12 trading days [1] - Other notable stocks with significant consecutive net buying days include Saiwei Electronics, Hunan Gold, Huaxi Securities, Huada Technology, Shanghai Airport, Zhejiang Xinneng, Xiangyang Bearing, and Nanwei Medical [1]

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the importance of seizing opportunities following market corrections, particularly in anticipation of improvements in 2026. It notes that the pharmaceutical sector's fundamentals remain strong despite recent market fluctuations, and it is currently at a valuation bottom. The report suggests focusing on innovative drugs and companies with potential for operational improvements in 2025 [7][11]. Summary by Sections Industry Overview - The pharmaceutical sector consists of 498 listed companies with a total market capitalization of approximately 70,594.11 billion [2]. - The sector has experienced a decline of 6.88% recently, with various sub-sectors such as pharmaceutical commerce and biopharmaceuticals also facing downturns [11]. Market Dynamics - The report highlights a significant market correction, with the Shanghai Composite Index down by 3.77% and the pharmaceutical sector underperforming [11]. - It notes that the overall performance of the pharmaceutical sector has been positive since the beginning of the year, with a return of 13.69%, slightly outperforming the broader market [18]. Investment Opportunities - The report identifies key companies to watch, including: - CDMO leaders: WuXi AppTec, WuXi Biologics, and WuXi AppTec [11]. - Front-end CROs: Tigermed, ProPhase, and Zhaoyan New Drug [11]. - Medical devices: United Imaging Healthcare and HaiTai New Light [11]. - Biopharmaceuticals: I-Mab Biopharma and Hualan Biological Engineering [11]. - It also suggests focusing on companies with innovative drug pipelines and those that are transitioning from biotech to biopharma [11]. Company Performance - The report provides a list of recommended stocks, including: - WuXi AppTec (66.45), rated "Buy" - Three Life Pharmaceuticals (29.34), rated "Buy" - Tigermed (49.59), rated "Buy" - Xiansheng Pharmaceutical (12.85), rated "Buy" - Betta Pharmaceuticals (48.60), rated "Buy" [5][31]. Regulatory and Market Trends - The report discusses recent regulatory developments, including a call from the vaccine industry association to avoid low-cost bidding practices to stabilize profit margins for leading vaccine companies [11][12]. - It also notes significant acquisitions and advancements in drug development, such as Johnson & Johnson's acquisition of Halda Therapeutics for $30.5 billion [11].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

Core Viewpoint - Nanwei Medical's stock price has experienced fluctuations, with a recent decline of 2.08% and a year-to-date increase of 24.22% [1][2]. Group 1: Stock Performance - As of November 17, Nanwei Medical's stock price is 82.11 CNY per share, with a market capitalization of 15.424 billion CNY [1]. - The stock has seen a decline of 1.00% over the last five trading days, 5.62% over the last 20 days, and 15.71% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Nanwei Medical reported a revenue of 2.381 billion CNY, representing a year-on-year growth of 18.29%, and a net profit attributable to shareholders of 509 million CNY, up 12.90% year-on-year [2]. - The company has distributed a total of 978 million CNY in dividends since its A-share listing, with 664 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Nanwei Medical is 12,500, an increase of 1.38% from the previous period [2]. - The average number of circulating shares per shareholder is 15,009, which has decreased by 1.36% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 3.6594 million shares, while Huabao CSI Medical ETF has reduced its holdings by 459,000 shares [3].

证券代码：688029 证券简称：南微医学 公告编号：2025-048 南微医学科技股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 网络投票相结合的方式进行表决。本次会议的召集和召开程序以及表决方式和表 决程序均符合《公司法》及《公司章程》的规定，会议合法有效。 （五） 公司董事、监事和董事会秘书的出席情况 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 12 日 （二） 股东大会召开的地点：南京江北新区药谷大道 199 号公司 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 118 | | --- | --- | | 普通股股东人数 | 118 | | 2、出席会议的股东所持有的表决权数量 | 97,933,827 | | 普通股股东所持有表决权数量 | 97,933,827 | | 3、出席会 ...

江苏新高的律师事务所 关于 南微医学科技股份有限公司 2025 年第三次临时股东大会的 见证法律意见书 地址：南京市秦淮区龙蟠中路 419 号人保（南京）金融大厦 A 座 9、10 楼 电话：（025）84715285 传真：（025）84703306 邮编：210001 江苏新高的律师事务所 关于南微医学科技股份有限公司 2025 年第三次临时股东大会的见证法律意见书 江苏新高的律师事务所 关于南微医学科技股份有限公司 2025 年第三次临时股东大会的见证法律意见书 苏高律股字[2025]第[1101]号 致：南微医学科技股份有限公司 尽责的精神，本所律师对公司所提供的相关文件和有关事实进行了核查和验证， 现出具法律意见如下： 一、本次股东大会的召集、召开程序 （一）本次股东大会的召集 江苏新高的律师事务所（以下简称"本所"）接受南微医学科技股份有限公 司（以下简称"公司"）委托，指派张玫、陈施屹律师（以下简称"本所律师"） 出席公司 2025 年第三次临时股东大会（以下简称"本次股东大会"），就本次 股东大会的合法性进行见证并出具法律意见书。 本法律意见书依据《中华人民共和国公司法》（以下简称"《公司法》 ...

Core Insights - Nanwei Medical's stock rose by 3.89% to close at 86.17 yuan, with two block trades totaling 150,000 shares and a transaction amount of 12.93 million yuan [1] Trading Activity - The first block trade occurred at a price of 86.17 yuan for 75,000 shares, amounting to 6.46 million yuan, with a premium rate of 0.00%. The buyer was GF Securities Co., Ltd. Headquarters, and the seller was China Merchants Securities Co., Ltd. Beijing Jinghui Street Securities Business Department [1] - The second block trade mirrored the first, also at 86.17 yuan for 75,000 shares and 6.46 million yuan, with the same buyer and seller as the first transaction [1] Recent Performance - Over the past three months, Nanwei Medical has recorded four block trades with a total transaction amount of 27.98 million yuan [1] - In the last five trading days, the stock has increased by 5.52%, with a net inflow of 29.67 million yuan from major funds [1]